CureDuchenne hosts its Futures National Conference in May, with sessions on research, care, and support for Duchenne and ...

Due to extremely limited mobility, columnist Robin Stemple has already fallen twice in recent weeks. The next time could be ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that approval of Agamree (vamorolone) in the ...

The Speak Foundation launched the LGMD Centers of Excellence, a network of clinics dedicated to improving care for people ...

Wheelchairs tend to be equated with disability, but columnist Patrick Moeschen sees them as tools that increase function and ...

Upsher-Smith Laboratories has launched two new websites to support people with Duchenne muscular dystrophy (DMD) who are taking its recently introduced corticosteroid therapy Kymbee (deflazacort). One ...

A human being since 1972, Patrick Moeschen recently retired after 28 years of teaching music at the middle school level in a public school setting. Diagnosed with Becker muscular dystrophy (MD) in ...

Bridgebio Pharma has submitted an application asking the U.S. Food and Drug Administration (FDA) to approve its experimental oral therapy, BBP-418, to treat limb-girdle muscular dystrophy type 2i ...

Next week, researchers, clinicians, industry leaders, and families will gather at the 2026 MDA Clinical & Scientific Conference, hosted by the Muscular Dystrophy Association (MDA), to discuss the ...

Dosing has begun in a Phase 2 clinical trial testing the oral therapy SAT-3247 in boys with Duchenne muscular dystrophy (DMD). Participants in the BASECAMP study will be randomly assigned to take ...

For people with Duchenne muscular dystrophy (DMD), 2026 promises to be a year of tremendous excitement, with several new therapies poised for likely approval in the U.S., according to DMD advocates.